Company Short-Term Debts: Creative Medical Technology Holdings, Inc. (CELZ)

Public company logo of Creative Medical Technology Holdings, Inc. (CELZ)

CELZ develops urological stem cell treatments, relying on copyright protection for profit. The stock price trend shown in the graph is 0.00. StemSpine and Stem體's safety has earned them a high reputation among physicians, while strict FDA regulation and patent barriers limit new players' entry into this sector.

CELZ: Creative Medical Technology Short-Term Debt 07/04/2022 - 10/28/2026

Creative Medical Technology Holdings, Inc. - analytical breakdowns and key metrics (CELZ)

- price and consensus price forecast:
Price Chart Creative Medical Technology Holdings Inc.|CELZ - Consensus Target
- market capitalization data:
Market Capitalization Creative Medical Technology Holdings|CELZ - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Creative Medical Technology|CELZ - Total Stockholders' Equity|Market Value to Book Value Ratio creativemedicaltechnology.com|CELZ - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Creative Medical Technology|CELZ - Long-Term Debt to Equity|Short-Term Debt to Equity Creative Medical Technology Holdings Inc.|CELZ - Company Total Debt Obligations|Debts to Book Capitalization Creative Medical Technology Holdings|CELZ - Company Long-Term Liabilities|Company Short-Term Debt Creative Medical Technology
Analysis of all company metrics:creativemedicaltechnology.com - CELZ
Mass-produced product of Creative Medical Technology Holdings Inc.

The development of the StemSpine platform and expansion through urological centers require significant working capital, which is reflected in the structure of current liabilities. The total amount of short-term debt aggregates all financial obligations maturing within one year, allowing investors to assess the liquidity of Creative Medical Technology (CELZ) and the company's ability to service urgent loans under strict FDA oversight via the chart's dynamics.

Competitor analysis for Creative Medical Technology

MESO: Company Short-Term Debt|LCTX - Company Current Liabilities|SRZN (Surrozen Corp) - Company Short-Term Debts|Cryo-Cell International, Inc. (CCEL) - Company Current Liabilities|Company Short-Term Debts FBLG (FibroBiologics Inc.)|Short-Term Debt LGVN|Company Short-Term Debt BioRestorative Therapies (BRTX)